☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Samsung Bioepis
Samsung Bioepis Reports the Initiation of the P-I Trial Evaluation of SB27 (biosimilar, pembrolizumab) for the Treatment of Lung C...
March 4, 2024
Samsung Bioepis Highlights 2 Abstracts for SB17 (biosimilar, ustekinumab) for the Treatment of Moderate-to-Severe Psoriasis at ECC...
February 22, 2024
Samsung Bioepis Signs a Collaboration Agreement with Samil Pharma to Co-Commercialize SB15 (biosimilar, aflibercept) for the Treat...
February 1, 2024
Samsung Bioepis Successfully Resolves Patent Disputes with Johnson & Johnson
December 1, 2023
The US FDA Accepted to Review Samsung Bioepis & Organon’s sBLA for Hadlima (Biosimilar, adalimumab) to Treat Plaque Psoriasis
November 9, 2023
Samsung Bioepis Presents Post-hoc Analysis of P-III Clinical Trial for SB15, a Proposed Biosimilar to Eylea (Aflibercept) at EURET...
October 9, 2023
Load more...
Back to Home